The role of macrophage migration inhibitory factor in critical illness

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 14, 2014, Pages 1116-1124

  Rex, Steffen ^a,d   Kraemer, Sandra ^b,c   Grieb, Gerrit ^b,c   Emontzpohl, Christoph ^b   Soppert, Josefin ^b   Goetzenich, Andreas ^c   Rossaint, Rolf ^c   Bernhagen, Jürgen ^b,e   Stoppe, Christian ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemokine; Critical illness; Inflammation; Macrophage migration inhibitory factor; Multiple organ failure; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ALPHA CHEMOKINE; AMINO ACID TRANSFER RNA LIGASE; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; COP9 SIGNALOSOME; CXCL1 CHEMOKINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; THIOREDOXIN; THIOREDOXIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; Y BOX BINDING PROTEIN 1; AUTACOID; IMMUNOGLOBULIN RECEPTOR; MACROPHAGE MIGRATION INHIBITORY FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CRITICAL ILLNESS; DISEASE SEVERITY; HEART MUSCLE ISCHEMIA; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; INFLAMMATORY DISEASE; PROTEIN INTERACTION; REPERFUSION INJURY; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

CRITICAL ILLNESS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; RECEPTORS, IMMUNOLOGIC; REPERFUSION INJURY;

EID: 84924907194     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150203143736     Document Type: Article

References (73)

1. Calandra, T.; Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol., 2003, 3, 791-800.
2. Vincent, J. L.; Sakr, Y.; Sprung, C. L.; Ranieri, V. M.; Reinhart, K.; Gerlach, H.; Moreno, R.; Carlet, J.; Le Gall, J. R.; Payen, D. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med., 2006, 34, 344-353.
3. Martin, G. S.; Mannino, D. M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 2003, 348, 1546-1554.
4. Opal, S. M.; Laterre, P. F.; Francois, B.; LaRosa, S. P.; Angus, D. C.; Mira, J. P.; Wittebole, X.; Dugernier, T.; Perrotin, D.; Tidswell, M.; Jauregui, L.; Krell, K.; Pachl, J.; Takahashi, T.; Peckelsen, C.; Cordasco, E.; Chang, C. S.; Oeyen, S.; Aikawa, N.; Maruyama, T.; Schein, R.; Kalil, A. C.; Van Nuffelen, M.; Lynn, M.; Rossignol, D. P.; Gogate, J.; Roberts, M. B.; Wheeler, J. L.; Vincent, J. L. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA., 2013, 309, 1154-1162.
5. Sprung, C. L.; Annane, D.; Keh, D.; Moreno, R.; Singer, M.; Freivogel, K.; Weiss, Y. G.; Benbenishty, J.; Kalenka, A.; Forst, H.; Laterre, P. F.; Reinhart, K.; Cuthbertson, B. H.; Payen, D.; Briegel, J. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med., 2008, 358, 111-124.
6. Ranieri, V. M.; Thompson, B. T.; Barie, P. S.; Dhainaut, J. F.; Douglas, I. S.; Finfer, S.; Gardlund, B.; Marshall, J. C.; Rhodes, A.; Artigas, A.; Payen, D.; Tenhunen, J.; Al-Khalidi, H. R.; Thompson, V.; Janes, J.; Macias, W. L.; Vangerow, B.; Williams, M. D. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med., 2012, 366, 2055-2064.
7. Calandra, T.; Echtenacher, B.; Roy, D. L.; Pugin, J.; Metz, C. N.; Hultner, L.; Heumann, D.; Mannel, D.; Bucala, R.; Glauser, M. P. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med., 2000, 6, 164-170.
8. Al-Abed, Y.; Dabideen, D.; Aljabari, B.; Valster, A.; Messmer, D.; Ochani, M.; Tanovic, M.; Ochani, K.; Bacher, M.; Nicoletti, F.; Metz, C.; Pavlov, V. A.; Miller, E. J.; Tracey, K. J. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem., 2005, 280, 36541-36544.
9. Stoppe, C.; Grieb, G.; Rossaint, R.; Simons, D.; Coburn, M.; Gotzenich, A.; Strussmann, T.; Pallua, N.; Bernhagen, J.; Rex, S. High postoperative blood levels of macrophage migration inhibitory factor are associated with less organ dysfunction in patients after cardiac surgery. Mol. Med., 2012, 18, 843-850.
10. Miller, E.J.; Li, J.; Leng, L.; McDonald, C.; Atsumi, T.; Bucala, R.; Young, L. H. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature, 2008, 451, 578-582.
11. Qi, D.; Hu, X.; Wu, X.; Merk, M.; Leng, L.; Bucala, R.; Young, L. H. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J. Clin. Invest., 2009, 119, 3807-3816.
12. Koga, K.; Kenessey, A.; Powell, S. R.; Sison, C. P.; Miller, E. J.; Ojamaa, K. Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid. Redox Signal., 2011, 14, 1191-1202.
13. Janeway, C.A., Jr.; Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol., 2002, 20, 197-216
14. Calandra, T.; Bochud, P. Y.; Heumann, D. Cytokines in septic shock. Curr Clin Top Infect. Dis., 2002, 22, 1-23.
15. David, J. R. Delayed hypersensitivity in vitro: its mediation by cellfree substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S.A., 1966, 56, 72-77.
16. Bernhagen, J.; Calandra, T.; Mitchell, R. A.; Martin, S. B.; Tracey, K. J.; Voelter, W.; Manogue, K. R.; Cerami, A.; Bucala, R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature, 1993, 365, 756-759.
17. Calandra, T.; Bernhagen, J.; Metz, C. N.; Spiegel, L. A.; Bacher, M.; Donnelly, T.; Cerami, A.; Bucala, R. MIF as a glucocorticoidinduced modulator of cytokine production. Nature, 1995, 377, 68-71.
18. Leng, L.; Metz, C. N.; Fang, Y.; Xu, J.; Donnelly, S.; Baugh, J.; Delohery, T.; Chen, Y.; Mitchell, R. A.; Bucala, R. MIF signal transduction initiated by binding to CD74. J. Exp. Med., 2003, 197, 1467-1476.
19. Burger-Kentischer, A.; Goebel, H.; Seiler, R.; Fraedrich, G.; Schaefer, H. E.; Dimmeler, S.; Kleemann, R.; Bernhagen, J.; Ihling, C. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation, 2002, 105, 1561-1566.
20. Bernhagen, J.; Krohn, R.; Lue, H.; Gregory, J. L.; Zernecke, A.; Koenen, R. R.; Dewor, M.; Georgiev, I.; Schober, A.; Leng, L.; Kooistra, T.; Fingerle-Rowson, G.; Ghezzi, P.; Kleemann, R.; McColl, S. R.; Bucala, R.; Hickey, M. J.; Weber, C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med., 2007, 13, 587-596.
21. Kanzler, I.; Liehn, E.A.; Koenen, R.R.; Weber, C. Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications. Curr. Pharm. Biotechnol., 2012, 13, 37-45.
22. Strieter, R. M.; Polverini, P. J.; Arenberg, D. A.; Walz, A.; Opdenakker, G.; Van Damme, J.; Kunkel, S. L. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol., 1995, 57, 752-762.
23. Mehrad, B.; Keane, M. P.; Strieter, R. M. Chemokines as mediators of angiogenesis. Thromb. Haemost., 2007, 97, 755-762.
24. Strieter, R. M.; Polverini, P. J.; Kunkel, S. L.; Arenberg, D. A.; Burdick, M. D.; Kasper, J.; Dzuiba, J.; Van Damme, J.; Walz, A.; Marriott, D.; et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem., 1995, 270, 27348-27357.
25. Bai, F.; Asojo, O. A.; Cirillo, P.; Ciustea, M.; Ledizet, M.; Aristoff, P. A.; Leng, L.; Koski, R. A.; Powell, T. J.; Bucala, R.; Anthony, K. G. A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). J. Biol. Chem., 2012, 287, 30653-30663.
26. Boisvert, W. A.; Santiago, R.; Curtiss, L. K.; Terkeltaub, R. A. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest., 1998, 101, 353-363.
27. Boisvert, W. A.; Rose, D. M.; Johnson, K. A.; Fuentes, M. E.; Lira, S. A.; Curtiss, L. K.; Terkeltaub, R. A. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol., 2006, 168, 1385-1395.
28. Tillmann, S.; Bernhagen, J.; Noels, H. Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front. Immunol., 2013, 4, 115.
29. Burns, J. M.; Summers, B. C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M. E.; Sunshine, M. J.; Littman, D. R.; Kuo, C. J.; Wei, K.; McMaster, B. E.; Wright, K.; Howard, M. C.; Schall, T. J. A novel chemokine receptor for SDF-1 and ITAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med., 2006, 203, 2201-2213.
30. Mohle, R.; Bautz, F.; Rafii, S.; Moore, M. A.; Brugger, W.; Kanz, L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood, 1998, 91, 4523-4530.
31. Laudanna, C.; Alon, R. Right on the spot. Chemokine triggering of integrin-mediated arrest of rolling leukocytes. Thromb. Haemost., 2006, 95, 5-11.
32. Lu, M.; Grove, E. A.; Miller, R. J. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 7090-7095.
33. Tarnowski, M.; Grymula, K.; Liu, R.; Tarnowska, J.; Drukala, J.; Ratajczak, J.; Mitchell, R. A.; Ratajczak, M. Z.; Kucia, M. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancerassociated fibroblasts. Mol. Cancer Res., 2010, 8, 1328-1343.
34. Degryse, B.; de Virgilio, M. The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett., 2003, 553, 11-17.
35. Oppenheim, J. J.; Biragyn, A.; Kwak, L. W.; Yang, D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis., 2003, 62 Suppl 2, ii17-21.
36. Wakasugi, K.; Schimmel, P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science, 1999, 284, 147-151.
37. Calandra, T.; Bernhagen, J.; Mitchell, R. A.; Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med., 1994, 179, 1895-1902.
38. Bozza, F.A.; Gomes, R. N.; Japiassu, A. M.; Soares, M.; Castro- Faria-Neto, H.C.; Bozza, P.T.; Bozza, M.T. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock, 2004, 22, 309-313.
39. Donnelly, S. C.; Haslett, C.; Reid, P. T.; Grant, I. S.; Wallace, W. A.; Metz, C. N.; Bruce, L. J.; Bucala, R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med., 1997, 3, 320-323.
40. Onodera, S.; Kaneda, K.; Mizue, Y.; Koyama, Y.; Fujinaga, M.; Nishihira, J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem., 2000, 275, 444-450.
41. Roger, T.; David, J.; Glauser, M. P.; Calandra, T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature, 2001, 414, 920-924.
42. Mitchell, R. A.; Liao, H.; Chesney, J.; Fingerle-Rowson, G.; Baugh, J.; David, J.; Bucala, R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 345-350.
43. Fingerle-Rowson, G.; Koch, P.; Bikoff, R.; Lin, X.; Metz, C. N.; Dhabhar, F.S.; Meinhardt, A.; Bucala, R. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am. J. Pathol., 2003, 162, 47-56.
44. Mitchell, R. A.; Metz, C. N.; Peng, T.; Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem., 1999, 274, 18100-18106.
45. Lue, H.; Dewor, M.; Leng, L.; Bucala, R.; Bernhagen, J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell. Signal., 2011, 23, 135-144.
46. Tsuge, T.; Menon, S.; Tong, Y.; Wei, N. CSN1 inhibits c-Jun phosphorylation and down-regulates ectopic expression of JNK1. Protein Cell, 2011, 2, 423-432.
47. Kleemann, R.; Hausser, A.; Geiger, G.; Mischke, R.; Burger- Kentischer, A.; Flieger, O.; Johannes, F. J.; Roger, T.; Calandra, T.; Kapurniotu, A.; Grell, M.; Finkelmeier, D.; Brunner, H.; Bernhagen, J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature, 2000, 408, 211-216.
48. Petrovsky, N.; Socha, L.; Silva, D.; Grossman, A. B.; Metz, C.; Bucala, R. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol. Cell. Biol., 2003, 81, 137-143.
49. Stoppe, C.; Werker, T.; Rossaint, R.; Dollo, F.; Lue, H.; Wonisch, W.; Menon, A.; Goetzenich, A.; Bruells, C. S.; Coburn, M.; Kopp, R.; Bucala, R.; Bernhagen, J.; Rex, S. What is the significance of perioperative release of macrophage migration inhibitory factor in cardiac surgery? Antioxid. Redox Signal., 2013, 19, 231-239.
50. Beishuizen, A.; Thijs, L. G.; Haanen, C.; Vermes, I. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J. Clin. Endocrinol. Metab., 2001, 86, 2811-2816.
51. Gando, S.; Sawamura, A.; Hayakawa, M.; Hoshino, H.; Kubota, N.; Nishihira, J. High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation. Inflammation, 2007, 30, 118-124.
52. Thiele, M.; Bernhagen, J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid. Redox Signal., 2005, 7, 1234-1248.
53. Leaver, S. K.; MacCallum, N. S.; Pingle, V.; Hacking, M. B.; Quinlan, G. J.; Evans, T. W.; Burke-Gaffney, A. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Med., 2010, 36, 336-341.
54. Sprong, T.; Pickkers, P.; Geurts-Moespot, A.; van der Ven-Jongekrijg, J.; Neeleman, C.; Knaup, M.; Leroy, D.; Calandra, T.; van der Meer, J. W.; Sweep, F.; van Deuren, M. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock, 2007, 27, 482-487.
55. Ostergaard, C.; Benfield, T. Macrophage migration inhibitory factor in cerebrospinal fluid from patients with central nervous system infection. Crit. Care, 2009, 13, R101.
56. Renner, P.; Roger, T.; Bochud, P. Y.; Sprong, T.; Sweep, F. C.; Bochud, M.; Faust, S. N.; Haralambous, E.; Betts, H.; Chanson, A. L.; Reymond, M. K.; Mermel, E.; Erard, V.; van Deuren, M.; Read, R. C.; Levin, M.; Calandra, T. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J., 2012, 26, 907-916.
57. Otukesh, H.; Fereshtehnejad, S. M.; Hoseini, R.; Hekmat, S.; Chalian, H.; Chalian, M.; Bedayat, A.; Salman Yazdi, R.; Sabaghi, S.; Mahdavi, S. Urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: a possible predictor of acute pyelonephritis. Pediatr. Nephrol., 2009, 24, 105-111.
58. Makita, H.; Nishimura, M.; Miyamoto, K.; Nakano, T.; Tanino, Y.; Hirokawa, J.; Nishihira, J.; Kawakami, Y. Effect of antimacrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am. J. Respir. Crit. Care. Med., 1998, 158, 573-579.
59. Pollak, N.; Sterns, T.; Echtenacher, B.; Mannel, D. N. Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect. Immun., 2005, 73, 6488-6492.
60. Roger, T.; Delaloye, J.; Chanson, A. L.; Giddey, M.; Le Roy, D.; Calandra, T. Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. J. Infect. Dis., 2013, 207, 331-339.
61. Sun, H. W.; Bernhagen, J.; Bucala, R.; Lolis, E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 5191-5196.
62. Sun, H. W.; Swope, M.; Cinquina, C.; Bedarkar, S.; Bernhagen, J.; Bucala, R.; Lolis, E. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng., 1996, 9, 631-635.
63. Ouertatani-Sakouhi, H.; El-Turk, F.; Fauvet, B.; Roger, T.; Le Roy, D.; Karpinar, D. P.; Leng, L.; Bucala, R.; Zweckstetter, M.; Calandra, T.; Lashuel, H. A. A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. Biochemistry, 2009, 48, 9858-9870.
64. Dabideen, D. R.; Cheng, K. F.; Aljabari, B.; Miller, E. J.; Pavlov, V. A.; Al-Abed, Y. Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J. Med. Chem., 2007, 50, 1993-1997.
65. Lehmann, L. E.; Novender, U.; Schroeder, S.; Pietsch, T.; von Spiegel, T.; Putensen, C.; Hoeft, A.; Stuber, F. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med., 2001, 27, 1412-1415.
66. de Mendonca-Filho, H. T.; Gomes, R. V.; de Almeida Campos, L. A.; Tura, B.; Nunes, E. M.; Gomes, R.; Bozza, F.; Bozza, P. T.; Castro-Faria-Neto, H. C. Circulating levels of macrophage migration inhibitory factor are associated with mild pulmonary dysfunction after cardiopulmonary bypass. Shock, 2004, 22, 533-537.
67. Grieb, G.; Simons, D.; Piatkowski, A.; Bernhagen, J.; Steffens, G.; Pallua, N. Macrophage migration inhibitory factor-A potential diagnostic tool in severe burn injuries? Burns, 2010, 36, 335-342
68. Sobierajski, J.; Hendgen-Cotta, U. B.; Luedike, P.; Stock, P.; Rammos, C.; Meyer, C.; Kraemer, S.; Stoppe, C.; Bernhagen, J.; Kelm, M.; Rassaf, T. Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. Free Radic. Biol. Med., 2013, 63, 236-242.
69. Chagnon, F.; Metz, C. N.; Bucala, R.; Lesur, O. Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ. Res., 2005, 96, 1095-1102.
70. Gao, X. M.; Liu, Y.; White, D.; Su, Y.; Drew, B. G.; Bruce, C. R.; Kiriazis, H.; Xu, Q.; Jennings, N.; Bobik, A.; Febbraio, M. A.; Kingwell, B. A.; Bucala, R.; Fingerle-Rowson, G.; Dart, A. M.; Morand, E. F.; Du, X. J. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemiareperfusion injury: a predominant role of anti-inflammation. J. Mol. Cell. Cardiol., 2011, 50, 991-999.
71. Amin, M. A.; Volpert, O. V.; Woods, J. M.; Kumar, P.; Harlow, L. A.; Koch, A. E. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ. Res., 2003, 93, 321-329.
72. Luedike, P.; Hendgen-Cotta, U. B.; Sobierajski, J.; Totzeck, M.; Reeh, M.; Dewor, M.; Lue, H.; Krisp, C.; Wolters, D.; Kelm, M.; Bernhagen, J.; Rassaf, T. Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory factor. Circulation, 2012, 125, 1880-1889.
73. Stoppe, C.; Fries, M.; Rossaint, R.; Grieb, G.; Coburn, M.; Simons, D.; Brucken, D.; Bernhagen, J.; Pallua, N.; Rex, S. Blood levels of macrophage migration inhibitory factor after successful resuscitation from cardiac arrest. PLoS One, 2012, 7, e33512.